PHARMACOTHERAPY OF SOCIAL PHOBIA

社交恐惧症是一种非常普遍的、使人丧失能力的慢性焦虑 与大量的职业、社会和学术相关的障碍 成年人和儿童都会受到损害。它增加了 抑郁、药物滥用和经济依赖。不过， 社交恐惧症比其他焦虑症受到的关注更少， 对于这种情况，还没有普遍接受的治疗方法。 然而，特定的心理社会和心理药理治疗 证明了它的有效性。认知行为团体疗法(CBGT) 由Heimberg开发，已被证明优于对照疗法，而 利博维茨最先研究的MAOI苯乙肼已被证明优于 在几个对照试验中使用安慰剂。在一部非常成功的小说中 协作已成为该领域的典范，Heimberg和 Liebowitz共同比较了苯乙肼、CBGT、安慰剂和 可靠的心理社会控制治疗，并发现苯乙肼和CBGT 在各种测量方法上都具有优势，并具有明显的临床益处。 苯乙肼的起效更快，与CBGT在某些方面更有效 措施，而CBGT在治疗后往往更持久 停产。 虽然苯乙肼和CBGT产生了积极的效果，但一些 患者，特别是一般的社交恐惧症患者，没有反应 足够了。服用苯乙肼后也有显著的复发。 停产。因此，仍然需要治疗 社交恐惧症比这两个更有效、更持久 通常使用的治疗方法。具体地说，是一种 MAOI和CBGT从未被评估过。由于各种原因， 联合治疗可能比单独治疗更有效 治疗，比单独用药更持久，尤其对 患有广泛性社交恐惧症的患者。如果是，则联合苯乙肼/CBGT 治疗将对许多患者有明显的好处，他们的临床 目前，需求没有得到很好的满足。 为了解决这些需求，Liebowitz和Heimberg现在将比较CBGT， 苯乙肼，这两种疗法的组合，以及服用安慰剂的患者 一项关于社交恐惧症治疗的尖锐研究。结果通过以下方式进行评估 盲目独立评估者访谈、自我报告问卷，以及 标准化的行为测试。亚型和治疗的贡献 还将对现场到结果进行检查。这项研究基本上应该 提高我们对有效治疗社交恐惧症的认识。

Social Phobia is a highly prevalent, disabling, and chronic anxiety disorder associated with substantial vocational, social, and academic impairment in adults as well as children. It increases the risk of depression, substance abuse and financial dependence. Nevertheless, social phobia has received less attention than other anxiety disorders, and there are no universally accepted treatments for this condition. However, specific psychosocial and psychopharmacological treatments have demonstrated efficacy. Cognitive Behavioral Group Therapy (CBGT), developed by Heimberg, has proven superior to control therapies, while the MAOI phenelzine, first studies by Liebowitz, has proven superior to placebo in several controlled trials. In a novel and highly successful collaboration that has become a model in the field, Heimberg and Liebowitz together compared phenelzine, CBGT, pill placebo, and a credible psychosocial control treatment, and found phenelzine and CBGT superior on a variety of measures and of distinct clinical benefits. Phenelzine was faster acting and more effective with CBGT on some measures, while CBGT tended to be more durable following treatment discontinuation. While phenelzine and CBGT produced positive effects, a number of patients, especially among generalized social phobics, did not respond sufficiently. There was also significant relapse following phenelzine discontinuation. Therefore, there is still a need for treatments for social phobia that are more effective and more durable that those two treatments as typically administered. Specifically the combination of an MAOI and CBGT has never been evaluated. For a variety of reasons, the combination treatment may be more effective that either individual therapy, more durable than medication alone, and especially effective for patients with generalized social phobia. If so, combined phenelzine/CBGT treatment would be of distinct benefit for many patients whose clinical needs are currently not well met. To address these needs, Liebowitz and Heimberg will now compare CBGT, phenelzine, the combination of these two treatments, and pill placebo in a acute study the treatment of social phobia. Outcome is evaluated by blind independent assessor interviews, self-report questionnaires, and standardized behavioral tests. The contributions of subtype and treatment site to outcome will also be examined. This study should substantially enhance our knowledge of effective treatments for social phobia.